Phase 2 Multiple Sclerosis Trial, Recruiting NCT06956326 Sponsor: Lars Hvid Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 2 Multiple Sclerosis Trial, Recruiting

NCT06956326
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been admitted to a Danish MS Hospital for an inpatient rehabilitation stay
  • People whose neurologist has confirmed they have had a motor relapse (affecting movement or coordination) within the past 6 months, with a significant enough change in physical function to meet a specific scoring threshold
  • People who have already finished any steroid treatment or other acute relapse treatment, if that treatment was prescribed
  • People who are over 18 years of age

Who may not be able to join:

  • People whose motor relapse started more than 6 months ago
  • People with medical conditions or significant cognitive difficulties that would prevent them from taking part in or understanding an intensive rehabilitation program (confirm with trial site)
  • People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +4593508717

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Lars Hvid
Registry
ClinicalTrials.gov
Start date
1 May 2025
Est. completion
31 December 2027

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Expanded Disability Status Scale (EDSS); MS Functional Composite (MSFC) Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov